Login to Your Account

Genmab Shares Dive Sharply on Zalutumumab Phase III Miss

By Cormac Sheridan

Tuesday, March 9, 2010
Shares in Genmab A/S slid more than 20 percent Monday on news that zalutumumab, an antibody-targeting epidermal growth factor receptor (EGFR), failed to reach the primary endpoint of a pivotal Phase III trial in head and neck cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription